Reason for request

Reassessment of inclusion on the list of drugs reimbursed by National Health Insurance and of the improvement in actual benefit of beta interferons and glatiramer acetate indicated in multiple sclerosis.


Clinical Benefit


The actual benefit of this medicinal product remains substantial.

Clinical Added Value


In view of the absence of demonstrated long-term efficacy against disability provided by the medicinal product BETAFERON, the improvement in actual benefit is level III in the treatment of patients with multiple sclerosis.

Contact Us

Évaluation des médicaments

See also